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Background: Alcohol consumption has been linked to a considerable burden of disease in the United Kingdom
(UK), with most of this burden due to heavy drinking and Alcohol Dependence (AD). However, AD is undertreated
in the UK, with only 8% of those individuals with AD being treated in England and only 6% of those individuals
with AD being treated in Scotland. Thus, the objective of this paper is to quantify the deaths that would have been
avoided in the UK in 2004 if the treatment rate for AD had been increased.
Methods: Data on the prevalence of AD, alcohol consumption, and mortality were obtained from the Adult
Psychiatric Morbidity Survey, the Global Information System on Alcohol and Health, and the 2004 Global Burden of
Disease study respectively. Data on the effectiveness of pharmacological treatment and Motivational Interviewing/
Cognitive Behavioural Therapy were obtained from Cochrane reviews and meta-analyses. Simulations were used to
model the number of deaths under different treatment scenarios. Sensitivity analyses were performed to model the
effects of Brief Interventions and to examine the effect of using AD prevalence data obtained from the National
Institute for Health and Clinical Excellence.
Results: In the UK, 320 female and 1,385 male deaths would have been avoided if treatment coverage of
pharmacological treatment had been increased to 20%. This decrease in the number of deaths represents 7.9% of
all alcohol-attributable deaths (7.0% of all alcohol-attributable deaths for women and 8.1% of all alcohol-attributable
deaths for men). If we used lower AD prevalence rates obtained from the National Institute for Health and Clinical
Excellence, then treatment coverage of pharmacological treatment in hospitals for 20% of the population with AD
would have resulted in the avoidance of 529 deaths in 2004 (99 deaths avoided for women and 430 deaths
avoided for men).
Conclusions: Increasing AD treatment in the UK would have led to a large number of deaths being avoided in
2004. Increased AD treatment rates not only impact mortality but also impact upon the large burden of disability
and morbidity attributable to AD, as well as the associated social and economic burdens.
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Alcohol consumption causes a large burden of disease
[1,2], with most of this burden caused by heavy drinking
and Alcohol Dependence (AD) [3], where heavy drinking
is defined as consuming a daily average of 5 or more
standard United Kingdom (UK) drinks for women
(40+ grams (g) of pure alcohol) and consuming a daily
average of 7.5 standard UK drinks or more for men (60+ g
of pure alcohol) [4]. In the European Union (EU) in 2004
for people 15 to 64 years of age, it has been estimated that
77.3% of the net alcohol-attributable burden of mortality,
67.2% of the detrimental alcohol-attributable burden
(i.e., the burden not including the beneficial effects of
alcohol for selected ischemic disease categories and
diabetes), and 9.2% of the total burden of mortality
resulted from heavy drinking [3]. One of the most
severe consequences of alcohol consumption is AD
(defined as a maladaptive behaviour of drinking of
alcoholic beverages with clinically relevant conse-
quences) [5]. AD is strongly associated with frequency
of heavy drinking episodes [6,7].
Alcohol consumption in the UK
In the UK in 2009 the average adult per capita con-
sumption was 12.5 litres (l), the same as the EU (12.5 l),
89.3% of women and 91.3% of men were current drin-
kers (people who consumed alcohol in the past year) [8],
and 8.9% of women and 15.5% of men were heavy
drinkers [8]. Patterns of drinking in the UK are quite
detrimental, as indicated by the UK’s pattern of drinking
score of 3 (out of 5) in 2009, with a high prevalence of
regular and irregular heavy drinking occasions [8]. In the
UK in 2009 approximately 14% of drinkers consumed 5
or more drinks several times a week, 20% consumed 5
or more drinks once a week, and a further 14% con-
sumed 5 or more drinks once a month [9].
Alcohol dependence in the UK
In England in 2007 approximately 3.6% of women and
9.3% of men 15 to 64 years of age had AD [10]; this
translates into more than 2 million people afflicted with
AD in England. The National Institute for Health and
Clinical Excellence estimated the prevalence of AD to be
2% for women and 6% for men [11]. By comparison, the
prevalence of AD in 2005 in the EU was lower than in
the UK, with 1.5% and 5.4% for women and men 15 to
64 years of age respectively being alcohol dependent [8].
Alcohol-attributable mortality in the UK
In the UK in 2004 an estimated 13.1 female and 27.6
male deaths (per 100,000 people) among people 15 to 64
years of age were attributable to alcohol consumption
[12], with 6.4% 8.5% of all premature deaths among
women and men respectively being caused by alcoholconsumption. In other words, 1 out of 16 and 1 out of
12 premature deaths of women and men respectively
were caused by alcohol consumption.Alcohol dependence treatment in the UK
Unfortunately, while there are effective treatment op-
tions available, both in terms of psychosocial [13] and
pharmacological interventions for AD [14,15], the over-
all treatment rate for AD is low (for an overview of vari-
ous treatment interventions for AD, see [11]). In Europe,
less than 10% of all people with AD receive treatment in
any given year [8,16], and in England it is estimated that
6% of the population 15 to 64 years of age with AD re-
ceive treatment in any given year [17]. In Scotland,
where prevalence of AD is higher than in England, treat-
ment coverage is over 8% [18]. Therefore, given the bur-
den of AD in the UK and the low treatment coverage
rates, increasing treatment rates and applying evidence-
based psychosocial and pharmacological interventions
could result in considerable reductions in alcohol-attrib-
utable mortality in the UK [3]. Thus, the aim of this arti-
cle is to quantify the effect of increasing AD treatment
coverage rates in the UK.Methods
Data sources
Data on drinking status for the UK were obtained from
the Global Status Report on Alcohol and Health [19];
for the UK the drinking status estimates were based on
large population surveys and government statistics.
Data on binge drinking patterns were obtained from
the European Commission report and from the World
Health Organization [9,19]. Per capita consumption of
alcohol data were obtained from the Global Information
System on Alcohol and Health (http://www.who.int/gho/
alcohol/en/index.html). Pattern of drinking score data
were obtained from the 2010 Global Burden of Disease
(GBD) study (see [20] for data on drinking pattern scores
and per capita consumption by country for 2005). The
pattern of drinking score, developed as part of the
Comparative Risk Assessment for alcohol within the GBD
studies, is a composite measure based on frequency of
heavy drinking occasions, the amount consumed per oc-
casion, the proportion of overall consumption due to
drinking to intoxication, and the proportion of drinking
occasions in combination with meals (see [21] for a defi-
nition of patterns of drinking and the construction of a
comparative score). Data on AD were obtained from [10],
and additional estimates of AD for the sensitivity analyses
were obtained from the National Institute for Health and
Clinical Excellence [11]. Mortality data by cause, age, and
sex for the UK for 2004 were obtained from the 2004
GBD study [4].
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The drinking prevalence of any population can be esti-
mated using sex- and age-specific per capita con-
sumption data; this data is used to derive a Gamma
distribution which is used to model the distribution of
alcohol consumption. This continuous prevalence distri-
bution, combined with continuous Relative Risk (RR)
functions, is used to derive the proportion of deaths
attributable to alcohol consumption (the proportion of
deaths that would not be present under a counterfactual
scenario where no one consumed alcohol) [22,23].
Modelling the effect of interventions for AD on mortality
Given the low current rate of treatment for people with AD
in the UK, we simulated the potential effects of the follow-
ing interventions: 1) pharmacological treatment 2) Motiv-
ational Interviewing/Cognitive Behavioural Therapy (MI/
CBT) and 3) Brief Interventions (BI) (the effects of BI were
only used for sensitivity analyses as the estimated effects of
BI have limitations (see limitations section) (for a detailed
description of the methodology, see Additional file 1).
The effect of treatment interventions for AD can be
expressed as a reduction in average alcohol consumption
or a decrease in the risk of mortality. To estimate the ef-
fect of increasing treatment coverage for AD on mortality,
we applied a reduction in alcohol consumption to a subset
of the population with AD, and compared the estimated
Alcohol-Attributable Fractions (defined as the proportion
of mortality that would not have occurred if people had
never consumed alcohol [24]) for the entire population be-
fore and after the increase in AD treatment coverage rates.
To estimate the effect of MI/CBT, an average drop in
consumption of 15.8 g of pure alcohol per day was as-
sumed (measured against no intervention (using the 95%
Confidence Interval (CI) of 9.6 g to 21.8 g)) [25,26]. As
an upper limit of the effect of MI/CBT, we modelled the
effect using an average drop in consumption of 21.8 g of
pure alcohol per day, i.e., the upper limit of the 95% CI.
We combined CBT and MI, as the meta-analyses on
their effectiveness yielded almost identical results. In
addition, Project Matching alcoholism treatment to cli-
ent heterogeneity did not observe any significant dif-
ferences between the use of either MI or CBT [27]. To
estimate the effects of pharmacological therapy for AD,
we combined the effects of randomized controlled trials
for acamprosate and opioid antagonist therapy [14,15]
by calculating the difference in alcohol consumption bet-
ween baseline and follow-up in the group that received
medication. The estimated effect was for the patient
population that received the pharmacological therapy;
55.0% reduced their alcohol consumption by an average
of 13% (18.1% of the patient population reduced their
drinking by 50% and 26.8% of the population achieved
abstinence).To estimate the effect of BI in hospital settings, two
different estimates were modelled. The first approach
was based on an estimated reduction in consumption of
13.5 g of pure alcohol per day from the meta-analysis
(using a 95% CI of 2.7 g to 24.5 g) [28,29] (this treatment
is represented by the term BI (1)). The second approach
was to assume an average RR for mortality of 0.6 (95%
CI of 0.40 to 0.91) for people with AD who received BI
therapy [28] (this treatment is represented by the term
BI (2)). This RR for mortality for people who are alcohol
dependent was obtained from the Cochrane review of all
studies which had a 12 month follow-up [28].
The drinking population was modelled using 100,000
samples drawn from the Gamma distribution represent-
ing the drinking population of the UK. It was assumed
that only heavier drinkers would receive interventions,
as their identification as being alcohol dependent is
more likely. The people with AD were, therefore, ran-
domly selected among the samples displaying an aver-
age alcohol consumption of 72 g and 48 g of pure
alcohol per day or more for men and women respec-
tively. This lower limit was based on alcohol consump-
tion among people with AD [30].
The number of deaths avoided under different treat-
ment scenarios was calculated by estimating the number
of alcohol-attributable deaths at the population level, as-
suming 0% of people with AD were receiving treatment,
and then by comparing this estimate to a simulated
population where 10%, 20%, 30% and 40% of people with
AD were receiving AD treatment. Alcohol-attributable
mortality was calculated by applying alcohol dose and
disease specific relative risks for mortality to each of the
100,000 random samples (see Additional file 2 for the
methodology used to estimate the mortality attributable
to AD).
The main analyses and sensitivity analyses using alter-
native AD prevalence data were performed using the
above-described methods. The sensitivity analyses differ
only with respect to the AD prevalence data that were
used.
No ethics approvals were required, as our analyses
were considered secondary data of existing databases.
Results
Impact of increasing treatment rates for AD on mortality
Pharmacological therapy was the most effective interven-
tion modelled at a AD treatment coverage rate of 20%,
with an estimated 794 deaths avoided in 2004 (173 deaths
avoided among women and 621 deaths avoided among
men), representing 7.9% of all alcohol-attributable deaths
(7.0% of all alcohol-attributable deaths for women and
8.1% of all alcohol-attributable deaths for men). The se-
cond and third most effective interventions at a coverage
rate of 20% were MI/CBT (higher effectiveness), with an
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mated 348 deaths avoided respectively. The numbers of
deaths avoided under the conditions that 10%, 20%, 30%
and 40% of people with AD were treated are outlined in
Figure 1 for women and Figure 2 for men by AD treat-
ment type. See Additional file 3 for the percentage of
alcohol-attributable deaths prevented using the alternative
AD prevalence rates.
Sensitivity analyses
If BI (modelled using a reduction in the risk of mortality,
namely BI (2)) were implemented for 20% of the popula-
tion, 832 deaths would be avoided in 2004 (158 deaths
avoided for women and 674 deaths avoided for men),
representing 8.2% of all alcohol-attributable deaths (6.5%
of all alcohol-attributable deaths for women and 8.8% of
all alcohol-attributable deaths for men). The effects of BI
were greater than those of any other intervention.
When the lower prevalences of AD and treatment
coverage were modelled under the scenario where 20%
of people with AD would be treated, pharmacological
treatment was the most effective main intervention mo-
delled (529 deaths avoided; 99 deaths avoided for
women, and 430 deaths avoided for men), followed by
MI/CBT (assuming a higher level of effectiveness) (264
deaths avoided), and then MI/CBT (217 deaths avoided).
In the sensitivity analysis, BI (2) was the more effective
than any of the main interventions modelled (547 deaths
avoided). A summary of the comparison between the
main and the alternative scenarios can be found in
Figures 3 and 4.
Discussion
AD is an important contributor to the burden of disease
in the UK, and a large proportion of this burden could
be reduced if the treatment coverage rate for AD wasFigure 1 Deaths avoided in the UK for women based on different tre
Motivational Interviewing/Cognitive Behavioural (MI/CBT) (based on t
and Brief Interventions (BI) treatment (based on the resulting reducti
reduction in mortality (BI hospital 2)).increased. Additionally, treatment of AD is important in
the UK, as the burden of alcohol-attributable mortality
is high [12] and has increased over the past 20 years in
key categories such as liver disease [31]. Interestingly,
even though overall average per capita consumption is
the same in the UK as in the rest of the EU, the pro-
portion of the burden of disease attributable to alcohol
consumption is higher for men and even more so for
women in the UK when compared to the rest of the EU
[3,12]. This apparent contradiction may be due to the
fact that people consume alcohol in the UK in a more
detrimental manner than their EU counterparts [32].
An increase in AD treatment rates will not only impact
mortality, but also will impact upon the large burden of
disability and morbidity attributable to AD, as well as the
associated social and economic burdens [33-36]; however,
increasing the treatment coverage for AD is non-trivial.
One way to increase treatment coverage for AD is by in-
creasing treatment options, such as offering the reduction
of alcohol consumption as a treatment outcome [37]. A
second way of increasing treatment coverage for AD is to
reduce the stigma associated with AD [37]. The third way
to increase treatment coverage is to ensure identification
of individuals with AD when they come into contact with
the medical system, such as during family physician (gene-
ral practitioner) visits, and then be treated by a general
practitioner for less severe cases of AD or referred to AD
treatment services for more severe cases of AD [38]. All of
these methods are difficult to implement and potentially
costly [38,39]. Additionally, increasing treatment coverage
of AD is not cost-effective when compared to other inter-
ventions, such as increasing taxation [29,38,40]. However,
given the need to increase health equity as mandated by
the World Health Organization, and the observation that
people with AD are more likely to be members of a racial
minority group and/or to have a low-income, increasingatment coverage rates for AD for pharmacological treatment,
he lower (MBI/CT 1) and upper reported estimates (MBI/CT 2)),
on in alcohol consumption (BI hospital 1) and the resulting
Figure 2 Deaths avoided in the UK for men based on different treatment coverage rates for AD for pharmacological treatment,
Motivational Interviewing/Cognitive Behavioural (MI/CBT) (based on the lower (MBI/CT 1) and upper reported estimates (MBI/CT 2)),
and Brief Interventions (BI) treatment (based on the resulting reduction in alcohol consumption (BI hospital 1) and the resulting
reduction in mortality (BI hospital 2)).
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equity perspective [41].
Limitations
There are limitations to the methodology for the esti-
mated number of deaths avoided if the treatment coverage
for AD was increased to 40%. First, the results for BI were
based on male heavy drinkers (with some studies included
in the meta-analysis excluding people with AD) and, thus,
the applicability of these results to men and especially to
women with AD is questionable [28]. However, it should
be noted that the association between heavy drinking andFigure 3 Number of deaths avoided in the UK for women based on t
treatment coverage rate) for pharmacological treatment, Motivationa
lower (MBI/CT 1) and upper reported estimates (MBI/CT 2)), and Brief
alcohol consumption (BI hospital 1) and the resulting reduction in moAD is strong [42], and heavy drinking has been suggested
as main domain for the operationalization for alcohol use
disorders [43].
Second, the high estimates of the effects of the BIs are
based on the latest Cochrane analyses of seven random-
ized controlled clinical trials (RCTs) in hospitals [28]. It
is plausible that a relatively short intervention can have
a large effect in this population, as people in hospitals
have higher risks of premature mortality, and the reduc-
tion of alcohol consumption in such a group has shown
important effects on mortality (for an overview see [8]).
Thus, BI in hospitals represents a “best case” scenario,wo different prevalence estimates for AD (assuming a 40%
l Interviewing/Cognitive Behavioural (MI/CBT) (based on the
Interventions (BI) treatment (based on the resulting reduction in
rtality (BI hospital 2)).
Figure 4 Number of deaths avoided in the UK for men based on two different prevalence estimates for AD (assuming a 40% treatment
coverage rate) for pharmacological treatment, Motivational Interviewing/Cognitive Behavioural (MI/CBT) (based on the lower (MBI/CT 1)
and upper reported estimates (MBI/CT 2)), and Brief Interventions (BI) treatment (based on the resulting reduction in alcohol consumption
(BI hospital 1) and the resulting reduction in mortality (BI hospital 2)).
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and moderating premature mortality (e.g. [44,45]). How-
ever, effects on mortality were also observed in a meta-
analyses of BIs in all settings and populations [46].
Therefore, we used the results from the meta-analysis by
McQueen and colleagues on BIs as a sensitivity analysis
only, as these results may not represent the actual num-
ber of deaths avoided if treatment coverage for BIs was
increased [28].
The third limitation to our study is that even though
overall average per capita consumption is the same in
the UK as in the rest of the EU, the proportion of the
burden of disease attributable to alcohol consumption is
higher for men and even more so for women in the UK
when compared to the rest of the EU [3,11]. The reason
for this contradiction may be due to the fact that people
consume alcohol in the UK in a more detrimental man-
ner than their EU counterparts [34]. Additionally, this
study modelled only the effect of increasing the treat-
ment coverage rate for AD on mortality. Increasing AD
treatment rates will also impact the large burden of dis-
ability and morbidity attributable to AD, as well as the
associated social and economic burdens [35-38]. Fourth,
while we estimated the effects for one year, most of the
RCTs had smaller follow-up times, and the effects may
not be as strong for one year. This may especially affect
the psychotherapies, but does not affect the estimated
reduction in the RR of mortality from BI in hospitals as
this reduction was based only on RCTs with a follow-up
of one year. This limitation may be as a result of dif-
ferences between efficacy and effectiveness [47-49] of
trials, i.e., not all of the effects seen in RCTs in selectedpopulations may transfer into the real world (see also
[50]). Additionally, it is unclear if BI would be as effec-
tive if the coverage of alcohol interventions was in-
creased to 40% of the population with AD, a proportion
of whom may be less motivated to engage in the inter-
ventions offered compared to those currently receiving
treatment.
A fifth limitation is the feasibility of increasing the treat-
ment rate to 40%, as a similar coverage rate has not been
achieved in any other similar high-income country [3].
The final limitation to our study is that the analysis was
limited to single AD interventions, and the effects of com-
bination therapies have not been examined through a
meta-analysis [3].Conclusions
The burden of mortality attributable to alcohol consump-
tion in the UK is large, and has been increasing over the
past 20 years in key categories such as liver cirrhosis. A
large proportion of the burden of disease in the UK is
attributable to unhealthy patterns of alcohol consumption
and to AD. Based on the analysis of data for 2004, this
article presents observations that an increase in AD treat-
ment in the UK could lead to the prevention of a large
number of deaths.Additional files
Additional file 1: Modelling the effects of AD interventions.
Additional file 2: Modelling mortality attributable to alcohol
consumption.
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